Orchid Pharma gets EIR from USFDA for its Chennai facility
New Delhi: Drug firm Orchid Pharma said it has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility.
The company has received the EIR from the United States Food and Drug Administration (USFDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.
"The facility was inspected by USFDA in the month of June 2017, it added.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd